, The novel receptor TRAIL- R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Molecular determinants of kinase pathway activation by apo2 ligand/tumor necrosis factor related apoptosis-inducing ligand, Immunity J Biol Chem, vol.7, issue.6, pp.813-820, 1997.
, Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes Monoclonal antibodies against TRAIL Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells Involvement of tumour necrosis factor-alpha-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccharide-stimulated dendritic cells to activated T cells 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA, Cell Vitam Horm J Exp Med J Exp Med Cancer Res J Immunol J Exp Med J Immunol Immunology J Invest Dermatol J Immunol Cancer Sci Immunology J Immunol Methods, vol.114, issue.25912, pp.181-19065, 1999.
, Detection of soluble TRAIL in HBV infected patients and its clinical implications TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival Safety and antitumor activity of recombinant soluble Apo2 ligand, TJ: TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunology and cell biology, pp.8135-81391077, 1999.
, Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice Critical role for tumor necrosis factorrelated apoptosis-inducing ligand in immune surveillance against tumor development Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alphagalactosylceramide Tumor necrosis factor-related apoptosisinducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer Tumor necrosis factor-related apoptosisinducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis TRAIL-R as a negative regulator of innate immune cell responses Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligandinduced apoptosis, AS: RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer research, pp.2246-2254161, 2001.
, Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer Somatic mutations of TRAIL-receptor 1 and TRAILreceptor 2 genes in non-Hodgkin's lymphoma Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis Progressive resistance of BTK- 143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy The tumor necrosis factorrelated apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer Molecular determinants of response to TRAIL in killing of normal and cancer cells Inactivating mutations of KILLER/DR5 gene in gastric cancers Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling Tissue distribution of the death ligand TRAIL and its receptors Tumor-specific downregulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract Differential expression of TRAIL and its receptors in benign and malignant prostate tissues Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5 Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma Expression of TRAIL and TRAIL receptors in normal and malignant tissues TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy Differential localization and regulation of death and decoy receptors for TNF-related apoptosisinducing ligand (TRAIL) in human melanoma cells Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors C: Rel/NFkappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1, 72 MERINO D, LALAOUI N, MORIZOT A et al.: Differential inhibition of TRAILmediated DR5-DISC formation by decoy receptors 1 and 2 RM et al.: A novel receptor for Apo2L/TRAIL contains a truncated death domain Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells Decoy Receptor-2 Small Interfering RNA (siRNA) Strategy Employing Three Different siRNA Constructs in Combination Defeats Adenovirus-Transferred Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Lung Cancer Cells. Hum Gene Ther, pp.4604-4610, 1997.
, Sensitization for death receptor-or druginduced apoptosis by re-expression of caspase-8 through demethylation or gene transfer Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation Suppression of caspase-8-and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells FLIP protein and TRAIL-induced apoptosis Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO) Tumour necrosis factor-related apoptosisinducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N- MC neuronal cells, TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways, pp.1844-18535865, 2001.
, A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, alltrans-retinoic acid, and ionizing radiation of human leukemia cells, Leukemia, vol.17, issue.9, pp.1794-1805, 2003.
, TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation, Apoptosis, vol.10, issue.1, pp.233-243, 2005.
, Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL), Surgery, vol.138, issue.2, pp.391-397, 2005.
, Distinct signaling pathways in TRAIL-versus tumor necrosis factor-induced apoptosis, Mol Cell Biol, vol.26, issue.21, pp.8136-8148, 2006.
, TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells, Hepatology, vol.36, issue.6, pp.1498-1508, 2002.
, Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines, Apoptosis, vol.7, issue.5, pp.413-420, 2002.
, MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors, The Journal of biological chemistry, pp.27616484-16490, 2001.
, Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation, Biochem Biophys Res Commun, vol.351, issue.4, pp.1024-1030, 2006.
, Serum sAPO-1/Fas levels in multiple sclerosis, Acta Neurol Scand, vol.95, issue.4, pp.208-210, 1997.
, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat Med, vol.5, issue.2, pp.157-163, 1999.
, Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy Death receptors in chemotherapy and cancer, J Clin Oncol Oncogene, vol.21, issue.2316, pp.3526-35342950, 2003.
, Effects of tumor necrosis factorrelated apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice, Cancer research, issue.20, pp.625800-5806, 2002.
, Interesting example of tumour regression in vivo using TRAIL combined to chemotherapy TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications, Blood, vol.124, issue.3, pp.98795-804, 2001.
, Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells, Clin Cancer Res, vol.7, issue.5, pp.1362-1369, 2001.
, The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis- Inducing Ligand-Induced Apoptosis, J Transl Med Br J Cancer Clin Cancer Res, vol.3, issue.12811, pp.22-127, 2005.
, Tumor necrosis factor-related apoptosisinducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects, Cancer research, vol.65, issue.17, pp.7888-7895, 2005.
, Recent paper suggesting limitations for the use of TRAIL in cancer therapy Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model, Cancer Res, vol.131, issue.10, pp.665363-5370, 2006.
, Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor, Proceedings of the National Academy of Sciences, vol.103, issue.23, pp.8634-8639, 2006.
DOI : 10.1073/pnas.0510187103
, Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases, Exp Cell Res, pp.3123892-3898, 2006.
, Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects, Cancer Gene Ther, 2006.
, Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells, J Korean Med Sci, vol.20, issue.6, pp.1046-1052, 2005.
, Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model, J Gene Med, vol.8, issue.2, pp.163-174, 2006.
, In vivo imaging of S- TRAIL-mediated tumor regression and apoptosis, Mol Ther, vol.11, issue.6, pp.926-931, 2005.
, A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases, Mol Ther, vol.9, issue.4, pp.496-509, 2004.
, Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects, Cancer Gene Ther, vol.14, issue.3, pp.316-326, 2007.
, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, Cancer research, vol.59, issue.3, pp.734-741, 1999.
, Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosisinducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo, Cancer research, issue.17, pp.635390-5400, 2003.
, TRAIL receptor-targeted therapy, Future Oncol, vol.2, issue.4, pp.493-508, 2006.
, Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma, Gynecol Oncol, vol.92, issue.3, pp.794-800, 2004.
, Expression of TRAIL (TNF-related apoptosisinducing ligand) receptors in cervical cancer Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study, Int J Gynecol Cancer Gynecol Oncol, vol.10, issue.963, pp.417-424705, 2000.
, Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs, Cell Death Differ, p.11, 2004.
, Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells, Clin Cancer Res Annals of the New York Academy of Sciences, vol.12, issue.1090, pp.2640-2646209, 2006.
, The promise of TRAIL-potential and risks of a novel anticancer therapy Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy, J Mol Med Proc Natl Acad Sci U S A, vol.158, issue.974, pp.1754-1759, 2000.
, Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms, Prostate, vol.61, issue.1, pp.35-49, 2004.
, DR5 knockout mice are compromised in radiation-induced apoptosis, Mol Cell Biol, vol.25, issue.5, pp.2000-2013, 2005.
, Monoclonal antibody to tumor necrosis factorrelated apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo, Int J Oncol, vol.28, issue.2, pp.421-430, 2006.
, Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicinand bortezomib-induced cell death, Br J Haematol, vol.130, issue.4, pp.501-510, 2005.
, DR5 antibodies induce Tumor-specific T Cell Immunity and tumor regression in a syngeneic mouse model Lexatumumab (TRAILreceptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4, Cancer Lett J Immunol, vol.173, issue.1748, pp.1664891-4898, 2001.
, Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity, Nat Med, vol.7, issue.8, pp.954-960, 2001.
, HGS-ETR1 , a Fully Human Monoclonal Antibody to the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Death Receptor 1 (TRAIL-R1) in Patients with Advanced Solid Cancer
, Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas, Journal of Clinical Oncology ASCO Annual Meeting Proceedings. J Pathol, vol.23, issue.2003, pp.3055327-335, 2003.
, Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) (ETR1-HM01), 2005.
, Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme, Expert Rev Anticancer Ther, vol.6, issue.9, pp.1313-1322, 2006.
, Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy, Cancer Immunol Immunother, vol.55, issue.1, pp.76-84, 2006.
, On the TRAIL of a new therapy for leukemia, Leukemia, vol.19, issue.12, pp.2195-2202, 2005.
, The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis 186 VASILEVSKAYA IA, O'DWYER PJ: 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines, Biochem Pharmacol Biochem Pharmacol, vol.66, issue.704, pp.1537-1545580, 2003.
, Sensitization of TRAILresistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin, Mol Cancer Ther, vol.5, issue.1, pp.170-178, 2006.
, 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8, Oncogene, vol.25, issue.37, pp.5125-5133, 2006.
, Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol, Oncogene, vol.23, issue.40, pp.6702-6711, 2004.
, Wogonin sensitizes resistant malignant cells to TNFalpha-and TRAIL-induced apoptosis, Blood, vol.108, issue.12, pp.3700-3706, 2006.
, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.435, issue.7042, pp.677-681, 2005.
, Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo, Nat Med, vol.8, issue.8, pp.808-815, 2002.
, Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL, Leukemia, vol.17, issue.11, pp.2122-2129, 2003.
, Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors, Cancer research, vol.66, issue.4, pp.2367-2375, 2006.
, Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses, Cancer Res, vol.66, issue.2, pp.960-969, 2006.
, of the use of the TRAIL system in immunotherapy